Park Edge Advisors LLC Acquires New Holdings in Boston Scientific Corporation $BSX

Park Edge Advisors LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 16,958 shares of the medical equipment provider’s stock, valued at approximately $1,064,000.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp raised its stake in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after buying an additional 920,495 shares during the period. Capital World Investors raised its stake in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the period. Norges Bank bought a new position in Boston Scientific during the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley grew its stake in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 2.8%

NYSE BSX opened at $44.34 on Thursday. The stock has a market capitalization of $65.90 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 0.87 and a beta of 0.56. The stock’s 50 day moving average price is $53.67 and its two-hundred day moving average price is $71.70. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $44.05 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Jefferies kept a Buy rating on Boston Scientific and still sees upside, even after cutting its price target to $67 from $100. Piper Sandler also maintained an Overweight rating, suggesting some analysts remain constructive on the long-term story.
• Positive Sentiment: Analyst coverage continues to frame BSX as oversold with potential upside, which may help support investor confidence if the company can avoid further setbacks.
• Neutral Sentiment: Recent market commentary noted Boston Scientific has been trading well below prior levels, with investors reassessing valuation after the sharp move lower.
• Negative Sentiment: Boston Scientific disclosed a nationwide, firm-initiated recall of Orca Single Use Air/Water and Suction Valves after reports that suction buttons could stick during gastrointestinal endoscopy procedures. The FDA classified the action as a Class II recall, which raises quality-control and regulatory concerns.
• Negative Sentiment: The recall adds to investor worries that even smaller accessory-device issues can hurt operations, increase oversight costs, and pressure sentiment around the company’s medical-device portfolio.
• Negative Sentiment: Options activity also turned more cautious, with unusual buying of put options suggesting some traders are positioning for additional downside in BSX.
• Negative Sentiment: Commentary from Jim Cramer added to the bearish tone, saying the sector is “too hard to own” right now and expressing surprise at the decline in Boston Scientific shares.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BSX. Truist Financial lowered their price target on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, June 4th. Jefferies Financial Group decreased their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, BTIG Research reissued a “buy” rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $83.76.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.